Advertisement

Topics

Latest "Aimmune Therapeutics Inc." News Stories

03:18 EDT 20th June 2018 | BioPortfolio

Here are the most relevant search results for "Aimmune Therapeutics Inc." found in our extensive news archives from over 250 global news sources.

More Information about Aimmune Therapeutics Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aimmune Therapeutics Inc. for you to read. Along with our medical data and news we also list Aimmune Therapeutics Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aimmune Therapeutics Inc. Companies for you to search.

Showing "Aimmune Therapeutics" News Articles 1–25 of 6,400+

Tuesday 19th June 2018

NeRRe Therapeutics pushes leads by €26m Series B financing


Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends – Industry Forecast to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends – Industry Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Tuberculosis (TB) Drugs/Therapeutics Market is poised to grow strong during the forecast period 2017 to 2027 … Continue reading → Cet article Global T...

Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis

CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. approval Strong pain reduction and overall symptom relief consistent with statistically significant results of CINGAL 13-01 Phase III placebo-controlled clinical s...


BridgeBio forms, commits $20mm in funding to Fortify Therapeutics

BridgeBio Pharma has launched Fortify Therapeutics with $20mm in financing.

Decibel Therapeutics raises $55mm in Series C round

Decibel Therapeutics raised $55mm in its Series C financing round. All prior investors participated including Third Rock Ven...

Kallyope, Novo Nordisk collaborate on development of obesity and diabetes therapies

Kallyope Inc. and Novo Nordisk AS are teaming up to discover and develop peptide therapeutics to treat obesity and diabetes. ...

Sarepta Closer To Muscular Dystrophy Wonder Drug

WASHINGTON (dpa-AFX) - Shares of Sarepta Therapeutics Inc., (SRPT) is currently trading up over 33% after the company released positive preliminary data for its experimental gene therapy for patie...

Kazia Releases Preliminary Cantrixil Phase I Data

SYDNEY, June 19, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer. The phase I study of Cantrixil commenced in December 2016 at five...

SynVivo’s Tissue on Chip Platform Advances Mechanistic Understanding of Sepsis - New Data Presented at 41st Annual SHOCK Conference

Real-time quantitative detection of the cellular behavior under physiological flow conditions enabled mechanistic insight into sepsis and vascular damage. The platforms capability for rapid screening of anti-inflammatory therapeutics was also demonstrated. HUNTSVILLE, Ala. (PRWEB) June 19, 2018 Multiple studies presented at the 2018 SHOCK conference in Scottsdale AZ report on the use of SynVivo...

Alpha Biopharma Announces Series A Financing

SHANGHAI, June 19, 2018 /PRNewswire/ -- Alpha Biopharma Inc. ("AlphaBio") today announced the first $37M closing of its $65M Series A financing led by Qiming Venture Partners, one of the most prominent venture capital firms in China. Other notable investors that participated in the round included the TF Fund and the LYZZ Healthcare Venture Fund. The proceeds from this financing will be u...

What Is A Rare Pediatric Disease? US FDA's Orphan Products Office Hopes To Update Guidance On Definition

The Office of Pediatric Therapeutics is working with the Office of Orphan Products Development to make rare pediatric disease determinations...  

Sarepta Therapeutics skyrockets on positive study data

Breaking News Sarepta Therapeutics-Aktie schießt nach oben!

Milwaukee (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Analyst Brian Skorney von Robert W. Baird: Analyst Brian Skorney vom Investmenthaus Robert W. Baird bestätigt laut einer Akti...

Silence Therapeutics on track to be a clinical stage company by year-end

As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements

Sarepta stock soars as early-stage gene therapy data shows promise

(Reuters) - Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD), driving the company's shares up 60 percent.

Arch Therapeutics CEO looks ahead to positive results on AC5 gel

Arch Therapeutics (OTCMKTS:ARTH, OTCQB:ARTH) CEO Dr. Terry Norchie tells Proactive Investors the biotechnology company is developing a gel called AC5 that seals and protects leaking and bleeding tissue in the human body. Norchie says the FDA has already seen Arch's application on AC5 and requested additional data to show the product does not cause an allergic reaction when placed on intact ski...

BioXcel Therapeutics Appoints Vincent O’Neill Chief Medical Officer

Vincent O’Neill has been appointed senior vice president and chief medical officer of BioXcel Therapeutics (NASDAQ: BTAI). O’Neill had been serving as chief medical officer of the Branford, CT, company on a consulting basis since last July. His experience also includes senior roles at Genentech, Sanofi (NYSE: SNY), GlaxoSmithKline (NYSE: GSK), and Mirna Therapeutics. Earlier […]

A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients

An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event.

Sarepta’s Data Are First in Rush for Duchenne Gene Therapy

It’s far too early to say whether gene therapy can treat Duchenne muscular dystrophy, a deadly genetic disease. But the first clinical data have arrived, with Sarepta Therapeutics today reporting encouraging preliminary results from three patients. Sarepta (NASDAQ: SRPT), of Cambridge, MA, is conducting an early-stage study of its experimental treatment known as AAVrh74.MHCK7.micro-Dystrophin. T...

3 patients add $2.5B to Sarepta's value

Dive Brief: The market capitalization for Sarepta Therapeutics rocketed up billions of dollars after its gene therapy for a rare muscle disease showed early signs of safety, as well as an efficacy profile that some analysts described as beyond a home run. Patients who have Duchenne muscul...

Sarepta shares soar as Duchenne gene therapy shows promise

(Reuters) - Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

Long-time Chairman and CEO Carrie S. Cox Appointed Executive Chairman Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson MD, PhD has been appointed President and Chief Executive Officer. Carrie S. Cox has assumed the role of Executive Chairman. Dr. Lawson, an innovator, scientist and vascular...

PTC shares soar after SMA drug data impresses market

After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on verge of a breakthrough in the SMA field. PTC and Roche are co-developing a new spinal muscular atrophy (SMA) drug called risdiplam or RG7916,...

Neuroimaging in Hepatitis C Chronic Infection

By way of neuroimaging studies, this review aimed to characterize the structural and functional impact of hepatitis C infection on the brain and central nervous system. Alimentary Pharmacology & Therapeutics

Alcresta Therapeutics Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The code, Q9994, is ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks